35 replies to this topic

[Trey]

A CML TKI drug being developed called ABL001 is worth watching.  This TKI drug, if it works, will target more specifically just ABL (as in BCR-ABL), so the side effects caused by current TKI drugs which inhibit more than BCR-ABL would be significantly reduced.  This is what I have long asked about: why can't we have a drug that simply targets the BCR-ABL more specifically rather than live with the side effects of also targeting c-KIt, PDGFR, SRC, etc, etc?  Maybe we will finally get a drug with minimal side effects, which would also have minimal long-term secondary impact on the body.  This would make ABL001 a great long term maintenance drug. 

 

ABL001 is being tested for use in TKI combo therapy along with Tasigna to overcome resistance, which shows promise.  Since ABL001 fits into a different part of the BCR-ABL than other CML TKI drugs, the resistance caused by losing effectiveness in the one TKI pocket would be overcome by ABL001 in the secondary TKI pocket.  It would also overcome T315i and other difficult kinase mutations.

 

http://journals.lww....Heavily.11.aspx

 

https://www.nibr.com...ne-target-twice

 

If ABL001 works, it is something that is very much needed for both initial TKI combo therapy -- which would yield a faster, deeper response -- and would also serve as a long term "mild" TKI maintenance drug.

 

I like this a lot.  Hope it works out.

 

Clinical trials are recruiting world-wide:

https://clinicaltria...how/NCT02081378

Edited by Trey, 14 September 2016 - 04:29 PM.

[DebDoodah22]

Good news, indeed! Thanks for sharing this...hope it develops as anticipated.

[scuba]

A CML TKI drug being developed called ABL001 is worth watching.  This TKI drug, if it works, will target more specifically just ABL (as in BCR-ABL), so the side effects caused by current TKI drugs which inhibit more than BCR-ABL would be significantly reduced.  This is what I have long asked about: why can't we have a drug that simply targets the BCR-ABL more specifically rather than live with the side effects of also targeting c-KIt, PDGFR, SRC, etc, etc?  Maybe we will finally get a drug with minimal side effects, which would also have minimal long-term secondary impact on the body.  This would make ABL001 a great long term maintenance drug. 

 

ABL001 is being tested for use in TKI combo therapy along with Tasigna to overcome resistance, which shows promise.  Since ABL001 fits into a different part of the BCR-ABL than other CML TKI drugs, the resistance caused by losing effectiveness in the one TKI pocket would be overcome by ABL001 in the secondary TKI pocket.  It would also overcome T315i and other difficult kinase mutations.

 

https://www.nibr.com...ne-target-twice

 

If ABL001 works, it is something that is very much needed for both initial TKI combo therapy -- which would yield a faster, deeper response -- and would also serve as a long term "mild" TKI maintenance drug.

 

I like this a lot.  Hope it works out.

 

Clinical trials are recruiting world-wide:

https://clinicaltria...how/NCT02081378

 

United States, Texas University of Texas/MD Anderson Cancer Center UT MD Anderson Not yet recruiting Houston, Texas, United States, 77030-4009 Contact: Rachel Abramowicz    713-794-5783    rrabramo@mdanderson.org    Principal Investigator: Jorge E. Cortes

 

I will be at M.D. Anderson tomorrow. But then again - this is a trial for Novartis - no doubt they want Tasigna paired, not a competitor's drug. 

[shaynalee]

This is great news! Gives us all hope for a long and "normal"-ish life! I would love for my hubby, and everyone here, to be able to treat this condition with fewer side effects.

[Billie Murawski]

WoW, Just knowing something like that is in the works is a great Mothers Day Gift.  Thanks Trey!

[alexamay09]

Though it could be a long time before it filters through to the UK, this sounds very promising and it is encouraging that drugs are still being developed.  Fewer/milder 'side effects' would be a dream.

 

Thanks for letting us know Trey.

 

Alex

[Pin]

Exciting news for all of us! I'd love to hear updates if anyone is eligible for the trial.

[August1]

Great to hear. Thanks for sharing, Trey. 

[Yougotafriend]

Thanks for the info Trey sounds good

[TeddyB]

If Trey is excited, then im excited (that probably didnt sound to good)

 

From some of the studies on mice, they seemed to have stopped the combo therapy after a few months, and the mice did not relapse, would this maybe work on humans as well? (ABL001 + Nilotinib/Tasigna combo targeting/killing the stem cells for a lasting cure?)

 

 

"Single agent dosing regimens led to tumor regressions; however, despite continuous dosing, all tumors relapsed within 30-60 days with evidence of point mutations in the resistant tumors. In contrast, animals treated with the combination of ABL001 and nilotinib achieved sustained tumor regression with no evidence of disease relapse either during the 70 days of treatment or for > 150 days after treatment stopped."

 

 

 

Side effect wise, would this mean that the sharts and the queasiness would go away, maybe the fatigue, tinnitus, bone pain, muscle pain etc etc etc etc etc? (We will find out when the trials start, but feel free to guess 

[Gail's]

TeddyB what tumors is your quote talking about? Was it tested on a different cancer than cml? It would be a godsend for us if it works on cml.

[TeddyB]

I am not sure about tumors in CML, i think i once read about tumors in blast phase CML, but i am not sure, maybe someone else can answer that.

 

Gail: Here is the paper: https://ash.confex.c...Paper76344.html

[Trey]

Leukemia is sometimes called a "liquid tumor", which is the case here.

[winespritzer]

Dear Trey,

Hope this happens really fast.

Thank you.

Wiunespritzer

[Yougotafriend]

Sounds great hope it's out soon

[r06ue1]

I once worked for Novartis, getting this to market will be a long time if it gets through Human trials.  Until that day, we still have our current medication keeping us alive (thankful of that!) and will continue to hope that the cure is just around the corner.  

[r06ue1]

It appears that they are now taking patients and pairing them with all first and second gen drugs:  

 

 

 

Drug: ABL001
Drug: ABL001 + Nilotinib
Drug: ABL001+imatinib
Drug: ABL001+dasatinib

 

https://clinicaltria...how/NCT02081378

 

Also recruiting all over the US and Internationally, anyone on these boards in the trials (if allowed to say so)?  

[Tucker1]

I recently had a consult with Dr. Druker at OHSU. He is involved in the trial there he said it was going very wiell and said it only affected 2enzymes not the 60 or more affected by others. He suggested the trial for me as one of my options if Bousitinib doesn't work or side effects are too much. It is great news.

[Harper3994]

My doctor at Moffitt in Tampa has mentioned this to me. Did not go into detail but said in July when I reach the 1 year Mark we will talk. I am hopeful maybe I can be part of this.

[rcase13]

I am trying to wrap my head around this. In the trials it looks like you take the ABL001 with another TKI. If you already have a good response from one TKI why would we take two TKIs. What would the benefit be. If you already PCRU why add another TKI? Or is this only if your not getting a good response? Are there any trials where all you take is ABL001?